Total hip arthroplasty (THA) and total knee arthroplasty (TKA) are two of the most successful operations in orthopaedic surgery.
Full article available to subscribers
Total hip arthroplasty (THA) and total knee arthroplasty (TKA) are two of the most successful operations in orthopaedic surgery.1–3 They have been shown to reduce pain, improve function and improve quality of life.1,2,4,5 Some reports suggest that opiate analgesia may be ineffective for chronic non-cancer pain.6–10 The use of opiate analgesia prior to total joint arthroplasty (TJA) has been associated with suboptimal clinical outcomes, complications and an increased length of stay (LOS) in hospital.5,6,8,11–18
To our knowledge, pre- and post-operative opiate use has not been analysed in rural Australasian population patients undergoing TJA.8,9,12,19–25 Patients in these settings often have difficulty accessing healthcare, present at a later stage of disease and suffer worse outcomes compared to urban patients.26–30
Opiate analgesia is known to cause socio-economic harm internationally in association with prescription and non-prescription use.31 As a result, our centre has guidelines for the prescription of opiate analgesics (Appendix Figure 1).
The primary aim of the study was to describe the use of opiates before, immediately after and 1 year after elective THA and TKA. A secondary aim was to compare prescribing practices following these procedures to local guidelines.
A retrospective cohort study of elective primary THA and TKA was performed between January 2018 and April 2019. Patients were assessed against exclusion criteria using physical and electronic medical records.
Southland Hospital is a 157-bed secondary-level facility located in Invercargill, Southland, New Zealand. Southland Hospital provides care for a large geographic catchment and more than 100,000 people.
Patients were excluded if they received a non-elective arthroplasty, had unavailable or incomplete records, had a single-stage bilateral arthroplasty or had deceased prior to 1-year follow-up.
Data were collected from physical and electronic records. Our facility’s electronic record is linked to community prescription dispensing.
Statistical analysis presented in Table 1 was performed using the Student’s unpaired t-Test. Data analysis was performed using Microsoft Excel software.
Prescriptions written for use “as required” (PRN) were interpreted as being used at the full dose. Dosages were quantified in morphine milligram equivalents (MME).32
The flow of patients to achieve the study sample is shown in Figure 1, and 157 patients were included in the analysis.
Characteristics of the study sample, split by whether patients received a THA or TKA and by use of opiates in the pre-operative period, are shown in Table 1. Pre-operative use of opiates was present in 59/90 (66%) of patients who received a THA and 33/67 (49%) who received a TKA.
View Figure 1–4, Table 1.
Figures 2 and 3 show the change in opiate use by time period for patients who received a THA and TKA. In both groups there was a similar change with time. In all, 108/157 (69%) were prescribed a higher dose of opiates on discharge than they had used in the 24 hours before discharge. After 1 year, 130/157 (83%) of patients were no longer prescribed opiates.
Opiate prescriptions on discharge compared to local guidelines are shown in Figure 4. In summary, 84/157 (67%) of all discharge prescriptions and 84/126 (67%) of opiate discharge prescriptions did not follow the local guidelines for dosing. In addition, 90/157 of all prescriptions and 90/126 (71%) of opiate prescriptions did not follow the local guidelines for duration of prescription.
Opiate analgesics are widely used to manage post-operative pain following orthopaedic procedures including TJA.9,21,22 Opiates are reported to be an effective analgesic agent for acute post-operative pain; however, they are associated with risks of addiction and overdose.6,8,10,33 The negative impact of these drugs on patients undergoing orthopaedic surgery has been well documented.8,11–14 Most reports have been from high-volume urban centres, limiting the generalisability to rural settings.26–30
In New Zealand, population-specific barriers to healthcare have been described.26–30 Observations from urban centres may not be transferrable to rural centres, necessitating an understanding of opiate use in patients undergoing TJA in rural settings.34 To our knowledge, there have been no published clinical reports examining these issues in patients undergoing elective TJA in rural Australasian centres.8,9,12,19–25
Half of TKA patients (49%) and two thirds of THA patients (66%) used opiates pre-operatively, with only 13% and 19% respectively using opiate analgesia 1-year post-operatively.
We have found rates of pre-operative opiate use in a rural population that are two to three times those of the wider New Zealand population prior to TJA.21 We believe this is an important observation and it suggests rural patients may be at higher risk of suboptimal outcomes when compared to urban cohorts. Anecdotally, access to arthroplasty in our rural centre is limited by long waiting lists, secondary to insufficient access to operating theatres and inpatient beds.
Twenty percent of patients (25/126) who were prescribed opiates continued to use these 1-year post-operatively. This is higher than has been reported in some other cohorts.8,9,21,24,35 While this study was not designed to assess the indication for ongoing use, the medical record of these patients was reviewed in attempts to identify possible reasons for ongoing opiate use. Seventeen (65%) suffered from arthritis in another joint, four (15%) had ongoing pain in the operated joint, one (4%) had spinal stenosis, one (4%) had advanced cancer and one (4%) underwent another surgical procedure around the time of follow-up. Only one (4%) patient did not have an identifiable reason for ongoing opiate use. Of note, this chart review was performed retrospectively and therefore the reasons for opiate use in these patients are uncertain.
This study has several limitations. It was a retrospective design. Using a consecutive non-selected patient cohort aimed at assessing the patterns of opiate use, the sample size was relatively small but accurately reflects the demographics of the patient population that is managed in rural centres of New Zealand. Although some statistically significant associations were identified, multiple statistical tests were performed and these may be spurious due to Type I error inflation. For comparisons that were not statistically significant, the small sample size may have also increased Type II error where important associations may not have been identified. As such, this study was not designed to assess the contribution of other comorbidities to the use of opiates in this population, nor was it capable of assessing associated complications. The cohort is unlikely to be generalisable to urban centres given the disparity in healthcare provision between rural and urban populations.
Both pre-operative opiate use and post-operative opiate prescribing exceeded expectations. Rates of pre-operative opiate use in rural patients undergoing THA or TKA are 2–3 times those reported in urban New Zealand settings. Prescriptions practices in our centre commonly deviate from guidelines and increased oversight of junior staff is required to foster safe prescribing practices. Further research in this field should review disparities in access to TJA, the timing of presentation, stage of disease, comorbidities and the time between presentation surgery.
View Appendix.
Excessive opiate analgesia in relation to orthopaedic surgery is associated with morbidity and mortality. Pre-operative use of opiates is associated with higher post-operative use. There is little information about opiate prescribing practices in relation to elective total joint arthroplasty (TJA) in New Zealand rural centres. The aims of this study were to describe opiate use before, immediately after and 1 year after TJA, and to compare prescribing practices with local guidelines.
A retrospective cohort study of elective primary hip and knee arthroplasties was conducted between January 2018 and April 2019. Opiate use was evaluated from clinical records and from electronic prescribing records and described in morphine milligram equivalents (MME) with a particular focus on pre-operative and post-operative periods, and use after 1 year.
In the study period, 199 patients underwent 203 joint arthroplasties. Of these, data from 157 patients were analysed. Patient data were not analysed because of unavailable files (N=20), non-elective procedures (N=11), bilateral arthroplasties (N=4), deaths (N=4) and incomplete information (N=3). Pre-operative opiates were used by 92 (59%) patients, of whom 70 (76%) were not using opiates after 1 year. There were 126 (80%) patients who were discharged with opiate prescriptions and the vast majority, 121 (96%), did not receive discharge prescriptions that conformed to local guidelines.
Despite undergoing joint arthroplasty, about one quarter of patients who had been prescribed opiates before the operation were still receiving opiates after 1 year. There was poor compliance with local guidelines.
Bradley S Atkinson, MB ChB: Joint Reconstruction Unit, Southland Teaching Hospital, Invercargill, New Zealand.
William M Oldfield, MB ChB, BBmedSC: Joint Reconstruction Unit, Southland Teaching Hospital, Invercargill, New Zealand.
Hannah M E Sim, MB ChB, PGDipOMG: Joint Reconstruction Unit, Southland Teaching Hospital, Invercargill, New Zealand.
Nemandra A Sandiford MSc FRCS (Tr/Orth): Joint Reconstruction Unit, Southland Teaching Hospital, Invercargill, New Zealand.
Funding from the Southland Medical Foundation supported this project.
Brad Atkinson: Southland Hospital, Kew Road, Invercargill, Southland, New Zealand.
The authors declare no relevant competing interests.
1) Ferguson RJ, Palmer AJ, Taylor A, et al. Hip replacement. Lancet. 2018 Nov 3;392(10158):1662-1671. doi: 10.1016/S0140-6736(18)31777-X.
2) Price AJ, Alvand A, Troelsen A, et al. Knee replacement. Lancet. 2018 Nov 3;392(10158):1672-1682. doi: 10.1016/S0140-6736(18)32344-4.
3) Hart JA. Joint replacement surgery. Med J Aust. 2004 Mar 1;180(S5):S27-30. doi: 10.5694/j.1326-5377.2004.tb05910.x.
4) Miettinen HJA, Mäkirinne-Kallio N, Kröger H, Miettinen SSA. Health-Related Quality of Life after Hip and Knee Arthroplasty Operations. Scand J Surg. 2021 Sep;110(3):427-433. doi: 10.1177/1457496920952232.
5) Atwood K, Shackleford T, Lemons W, et al. Postdischarge Opioid Use after Total Hip and Total Knee Arthroplasty. Arthroplast Today. 2021;7:126-9. doi: 10.1016/j.artd.2020.12.021.
6) Rolita L, Spegman A, Tang X, Cronstein BN. Greater number of narcotic analgesic prescriptions for osteoarthritis is associated with falls and fractures in elderly adults. J Am Geriatr Soc. 2013 Mar;61(3):335-40. doi: 10.1111/jgs.12148.
7) Krebs EE, Gravely A, Nugent S, et al. Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis Pain: The SPACE Randomized Clinical Trial. JAMA. 2018 Mar 6;319(9):872-882. doi: 10.1001/jama.2018.0899.
8) Shadbolt C, Schilling C, Inacio MC, et al. Opioid Use and Total Joint Replacement. Curr Rheumatol Rep. 2020;22(10):58. doi: 10.1007/s11926-020-00929-0.
9) Pryymachenko Y, Wilson RA, Abbott JH, et al. Risk Factors for Chronic Opioid Use Following Hip and Knee Arthroplasty: Evidence from New Zealand Population Data. J Arthroplasty. 2020 Nov;35(11):3099-3107.e14. doi: 10.1016/j.arth.2020.06.040.
10) Dunn KM, Saunders KW, Rutter CM, et al. Overdose and prescribed opioids: Associations among chronic non-cancer pain patients. Ann Intern Med. 2010 Jan 19;152(2):85-92. doi: 10.7326/0003-4819-152-2-201001190-00006.
11) Goplen CM, Kang SH, Randell JR, et al. Effect of preoperative long-term opioid therapy on patient outcomes after total knee arthroplasty: an analysis of multicentre population-based administrative data. Can J Surg. 2021 Mar 5;64(2):E135-E143. doi: 10.1503/cjs.007319.
12) Inacio MC, Pratt NL, Roughead EE, et al. Opioid use after total hip arthroplasty surgery is associated with revision surgery. BMC Musculoskelet Disord. 2016 Mar 10;17:122. doi: 10.1186/s12891-016-0970-6.
13) Ravi B, Pincus D, Croxford R, Leroux T, et al. Patterns of pre-operative opioid use affect the risk for complications after total joint replacement. Sci Rep. 2021;11(1):22124. doi: 10.1038/s41598-021-01179-5.
14) Chalmers BP, LeBrun DG, Lebowitz J, et al. The Effect of Preoperative Tramadol Use on Postoperative Opioid Prescriptions After Primary Total Hip and Knee Arthroplasty: An Institutional Experience of 11,000 Patients. J Arthroplasty. 2022 Jul;37(7S):S465-S470. doi: 10.1016/j.arth.2022.02.093.
15) Pivec R, Issa K, Naziri Q, et al. Opioid use prior to total hip arthroplasty leads to worse clinical outcomes. Int Orthop. 2014;38(6):1159-65. doi: 10.1007/s00264-014-2298-x.
16) Cozowicz C, Olson A, Poeran J, et al. Opioid prescription levels and postoperative outcomes in orthopedic surgery. Pain. 2017;158(12):2422-30. doi: 10.1097/j.pain.0000000000001047.
17) Smith SR, Bido J, Collins JE, et al. Impact of Preoperative Opioid Use on Total Knee Arthroplasty Outcomes. J Bone Joint Surg Am. 2017 May 17;99(10):803-808. doi: 10.2106/JBJS.16.01200.
18) Zywiel MG, Stroh DA, Lee SY, et al. Chronic opioid use prior to total knee arthroplasty. J Bone Joint Surg Am. 2011 Nov 2;93(21):1988-93. doi: 10.2106/JBJS.J.01473.
19) Tran T, Castello J, Taylor SE, et al. Opioid Use and Appropriateness of Supply After Total Knee or Hip Arthroplasty: An Australian Perspective. J Am Acad Orthop Surg. 2020 Dec 1;28(23):e980–9. doi: 10.5435/JAAOS-D-19-00789.
20) Naylor JM, Pavlovic N, Farrugia M, et al. Associations between pre-surgical daily opioid use and short-term outcomes following knee or hip arthroplasty: a prospective, exploratory cohort study. BMC Musculoskelet Disord. 2020 Jun 22;21(1):398. doi: 10.1186/s12891-020-03413-z.
21) Wilson R, Pryymachenko Y, Audas R, Abbott JH. Long-term opioid medication use before and after joint replacement surgery in New Zealand. N Z Med J. 2019 Dec 13;132(1507):33-47.
22) Kluger MT, Rice DA, Borotkanics R, et al. Factors associated with persistent opioid use 6-12 months after primary total knee arthroplasty. Anaesthesia. 2022 Aug;77(8):882-91. doi: 10.1111/anae.15783.
23) Hansen CA, Inacio MCS, Pratt NL, Roughead EE, Graves SE. Chronic Use of Opioids Before and After Total Knee Arthroplasty: A Retrospective Cohort Study. J Arthroplasty. 2017 Mar;32(3):811-817.e1. doi: 10.1016/j.arth.2016.09.040.
24) Huang P, Brownrigg J, Roe J, et al. Opioid use and patient outcomes in an Australian hip and knee arthroplasty cohort. ANZ J Surg. 2022 Sep;92(9):2261-8. doi: 10.1111/ans.17969.
25) Catchpool M, Knight J, Young JT, et al. Opioid use prior to elective surgery is strongly associated with persistent use following surgery: an analysis of 14 354 Medicare patients. ANZ J Surg. 2019 Nov 1;89(11):1410-1416. doi: 10.1111/ans.15492.
26) Nixon G, Samaranayaka A, de Graaf B, et al. Geographic disparities in the utilisation of computed tomography scanning services in southern New Zealand. Health Policy. 2014 Nov 1;118(2):222-8. doi: 10.1016/j.healthpol.2014.05.002.
27) Fearnley D, Kerse N, Nixon G. The price of ‘free’. Quantifying the costs incurred by rural residents attending publically funded outpatient clinics in rural and base hospitals. J Prim Health Care. 2016 Sep;8(3):204-9. doi: 10.1071/HC16014.
28) Lao C, Lees D, Patel S, et al. Geographical and ethnic differences of osteoarthritis-associated hip and knee replacement surgeries in New Zealand: a population-based cross-sectional study. BMJ Open. 2019;9(9):e032993. doi: 10.1136/bmjopen-2019-032993.
29) Lilley R, de Graaf B, Kool B, et al. Geographical and population disparities in timely access to prehospital and advanced level emergency care in New Zealand: a cross-sectional study. BMJ Open. 2019 Jul;9(7):e026026. doi: 10.1136/bmjopen-2018-026026.
30) Babbage DR, van Kessel K, Terraschke A, et al. Attitudes of rural communities towards the use of technology for health purposes in New Zealand: a focus group study. BMJ Open. 2020 Jun 1;10(6):e037892. doi: 10.1136/bmjopen-2020-037892.
31) Labrum JT, Ilyas AM. The Opioid Epidemic: Postoperative Pain Management Strategies in Orthopaedics. JBJS Rev. 2017 Aug;5(8):e14. doi: 10.2106/JBJS.RVW.16.00124.
32) Nielsen S, Degenhardt L, Hoban B, Gisev N. A synthesis of oral morphine equivalents (OME) for opioid utilisation studies. Pharmacoepidemiol Drug Saf. 2016 Jun;25(6):733-7. doi: 10.1002/pds.3945.
33) Deveza LA, Hunter DJ, Van Spil WE. Too much opioid, too much harm. Osteoarthritis Cartilage. 2018 Mar;26(3):293-295. doi: 10.1016/j.joca.2017.12.003.
34) Van Horne A, Van Horne J. Presurgical optimization and opioid-minimizing enhanced recovery pathway for ambulatory knee and hip arthroplasty: postsurgical opioid use and clinical outcomes. Arthroplast Today. 2019 Sep;6(1):71-76. doi: 10.1016/j.artd.2019.08.010.
35) Giordano NA, Highland KB, Nghiem V, et al. Predictors of continued opioid use 6 months after total joint arthroplasty: a multi-site study. Arch Orthop Trauma Surg. 2022 Dec;142(12):4033-9. doi: 10.1007/s00402-021-04261-9.
Sign in to view your account and access
the latest publications by the NZMJ.
Don't have an account?
Let's get started with creating an account.
Already have an account?
Become a member to enjoy unlimited digital access and support the ongoing publication of the New Zealand Medical Journal.
The New Zealand Medical Journal is fully available to individual subscribers and does not incur a subscription fee. This applies to both New Zealand and international subscribers. Institutions are encouraged to subscribe. The value of institutional subscriptions is essential to the NZMJ, as supporting a reputable medical journal demonstrates an institution’s commitment to academic excellence and professional development. By continuing to pay for a subscription, institutions signal their support for valuable medical research and contribute to the journal's continued success.
Please email us at nzmj@pmagroup.co.nz